Table 1 Baseline characteristics (n = 45)
Characteristicsa | Value |
|---|---|
Age, mean ± SD | 66.2 ± 12.3 |
Sex | |
Male | 21 (46.7) |
Female | 24 (53.3) |
Body Mass Index, mean ± SD, kg/m2 | 23.2 ± 4.1 |
BMI categories, No. (%) | |
Malnutrition b | 7 (15.6) |
Normal | 24 (53.3) |
Overweight c | 14 (31.1) |
ECOG PS, No. (%) | |
0 | 12 (26.7) |
1 | 31 (68.9) |
2 | 2 (4.4) |
mGPSd, No. (%) | |
0 | 17 (43.6) |
1 | 17(43.6) |
2 | 5 (12.8) |
Hospitalizations number, median [range] | 10 [0–18] |
Follow-up, median [range], days | 167 [0–189] |
Primary tumor location, No. (%) | |
Colon and rectum | 22 (48.9) |
Esophagus | 3 (6.7) |
Stomach | 5 (11.1) |
Biliary tract | 1 (2.2) |
Pancreas | 9 (20.0) |
Small intestine | 1 (2.2) |
Neuroendocrine tumor | 2 (4.4) |
Unknown | 2 (4.4) |
Stage, No. (%) | |
Local | 20 (44.4) |
Locally advanced | 6 (13.3) |
Metastatic | 19 (42.2) |
Type of treatment, No. (%) | |
Chemotherapy | 38 (84.4) |
Chemotherapy and biotherapy | 7 (15.6) |
Chemotherapy protocol, No. (%) | |
5FU + OXALIPLATIN | 22 (48.9) |
5FU + IRINOTECAN + OXALIPLATIN | 7 (15.6) |
5FU alone | 6 (13.3) |
GEMCITABINE | 5 (11.1) |
5FU-DACARBAZINE | 2 (4.4) |
5FU + IRINOTECAN | 1 (2.2) |
GEMCITABINE + OXALIPLATIN | 1 (2.2) |
VP16 + CISPLATINE | 1 (2.2) |
Neurotoxic chemotherapy e, No. (%) | 31 (68.9) |
Biotherapy protocol, No. (%) | |
BEVACIZUMAB | 6/7 (85.7) |
CETUXIMAB | 1/7 (14.3) |
Dynapenia, No. (%) | 11 (24.4) |